


**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Major Hospital		In accordance with letter dated April 14, 2022,	4. Expiration Date: August 31, 2023
2. 2451 Intelliplex Dr. Shelbyville, IN 46176		3. License No.: 13-14877-01 is amended in its entirety to read as follows:	5. Docket No.: 030-08191 Reference No.:
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. For any use permitted by 10 CFR 35.300.
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged Kits	D. 50 millicuries total	D. For use in in-vitro studies.



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 13-14877-01

Docket or Reference No.:  
030-08191

Amendment No. 35

CONDITIONS

10. Licensed material shall be used or stored at the licensee's facilities located at:
- A. 2451 Intelliplex Dr., Shelbyville, Indiana, 46176
  - B. 2455 Intelliplex Dr., Shelbyville, Indiana, 46176
11. The Radiation Safety Officer (RSO) for this license is Ty A. Montgomery, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
  - B. The following individuals are authorized users for the material and medical uses as indicated:
 

<u>Authorized User (M.D., D.O., etc.)</u>	<u>Material and Use</u>
Jonathan R. Bielefeld, M.D.	10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300
Michael Eaton, M.D.	10 CFR 35.300
Scott Miller, M.D.	10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300
Ty A. Montgomery, M.D.	10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300
Kenneth G. Scott, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300


**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 13-14877-01

Docket or Reference No.:  
030-08191

Amendment No. 35

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26., The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated February 26, 2013 (ML13060A502)
  - B. Letter dated December 14, 2015 (ML15355A230)
  - C. Letter dated February 1, 2017 (ML17039A836)
  - D. Letter dated April 14, 2022 (ML22123A020)
  - E. Letter dated July 5, 2022 (ML22187A053)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: July 21, 2022By: \_\_\_\_\_  
Magdalena R. Gryglak  
Region 3